- Home
- GRVY vs ADCT Comparison
GRVY vs ADCT Comparison
Compare GRVY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRVY
- ADCT
- Stock Information
- Founded
- GRVY 2000
- ADCT 2011
- Country
- GRVY South Korea
- ADCT Switzerland
- Employees
- GRVY N/A
- ADCT N/A
- Industry
- GRVY Business Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GRVY Consumer Discretionary
- ADCT Health Care
- Exchange
- GRVY Nasdaq
- ADCT Nasdaq
- Market Cap
- GRVY 412.9M
- ADCT 454.5M
- IPO Year
- GRVY 2005
- ADCT 2020
- Fundamental
- Price
- GRVY $59.51
- ADCT $3.97
- Analyst Decision
- GRVY
- ADCT Strong Buy
- Analyst Count
- GRVY 0
- ADCT 6
- Target Price
- GRVY N/A
- ADCT $7.60
- AVG Volume (30 Days)
- GRVY 13.1K
- ADCT 745.9K
- Earning Date
- GRVY 11-07-2025
- ADCT 11-10-2025
- Dividend Yield
- GRVY N/A
- ADCT N/A
- EPS Growth
- GRVY N/A
- ADCT N/A
- EPS
- GRVY 8.02
- ADCT N/A
- Revenue
- GRVY $399,496,744.00
- ADCT $75,209,000.00
- Revenue This Year
- GRVY N/A
- ADCT $11.78
- Revenue Next Year
- GRVY N/A
- ADCT $4.83
- P/E Ratio
- GRVY $7.25
- ADCT N/A
- Revenue Growth
- GRVY 12.13
- ADCT 6.35
- 52 Week Low
- GRVY $53.12
- ADCT $1.05
- 52 Week High
- GRVY $70.00
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- GRVY 41.86
- ADCT 45.58
- Support Level
- GRVY $57.04
- ADCT $3.87
- Resistance Level
- GRVY $60.50
- ADCT $4.19
- Average True Range (ATR)
- GRVY 1.36
- ADCT 0.30
- MACD
- GRVY 0.22
- ADCT -0.05
- Stochastic Oscillator
- GRVY 39.17
- ADCT 27.78
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).